Welcome to our dedicated page for Acadia Healthcare Company SEC filings (Ticker: ACHC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Acadia Healthcare Company's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Acadia Healthcare Company's regulatory disclosures and financial reporting.
YOUNG TODD S. reported acquisition or exercise transactions in this Form 4 filing.
Acadia Healthcare Company, Inc. Chief Financial Officer Todd S. Young reported a compensation-related equity grant of 58,799 shares of common stock on April 10, 2026. The shares were granted at no cash cost to him and are scheduled to vest over three years in equal yearly installments beginning on April 10, 2027. After this award, he directly holds a total of 107,244 common shares, showing this is a sizable but routine stock-based compensation grant rather than an open-market purchase.
Farley Brian reported acquisition or exercise transactions in this Form 4 filing.
Acadia Healthcare Company, Inc. reported that EVP, General Counsel and Secretary Brian Farley received a grant of 37,510 shares of common stock on April 10, 2026. The award was granted at no cash cost per share and is part of his equity compensation.
The shares will vest over a three-year period in equal yearly installments beginning on April 10, 2027, tying the benefit to continued service. After this award, Farley directly holds a total of 106,675 shares of Acadia Healthcare common stock.
Acadia Healthcare Co Inc: The Vanguard Group filed an amended Schedule 13G/A reporting that, following an internal realignment, certain Vanguard subsidiaries will report holdings separately under SEC Release No. 34-39538. The amendment states 0 shares beneficially owned of Acadia Healthcare common stock as reported in the filing dated 03/13/2026.
The filing explains the realignment occurred on January 12, 2026 and that Vanguard no longer is deemed to beneficially own securities held by those subsidiaries; it is signed by Ashley Grim on 03/26/2026.
Acadia Healthcare Company, Inc. is asking stockholders to vote at its 2026 Annual Meeting on May 6, 2026, in Franklin, Tennessee. Stockholders of record at the close of business on March 9, 2026, may vote, with 92,034,218 shares of common stock outstanding.
Key items include electing three Class III directors to terms expiring in 2029 as part of a phased declassification of the Board, approving a second amendment to the Amended and Restated Incentive Compensation Plan, a non-binding advisory vote on executive compensation, and ratifying Ernst & Young LLP as independent auditor for 2026.
The incentive plan amendment would increase the aggregate number of shares available for issuance or use under the plan by 3,000,000 shares, from 15,175,000 to 18,175,000, supporting equity and cash-based awards for approximately 25,000 employees, officers, consultants and advisors and nine non-employee directors.
The proxy also describes Acadia’s governance structure, committee composition, majority voting and director resignation policies, risk oversight, and a pay-for-performance executive compensation program that emphasizes performance-based cash incentives and a mix of time- and performance-vesting equity awards.
Cancelmi Daniel J reported acquisition or exercise transactions in this Form 4 filing.
Acadia Healthcare Company, Inc. director Daniel J. Cancelmi received a grant of 6,625 shares of common stock as equity compensation. The shares were awarded at no cash cost and are held directly. They will vest over a three-year period in equal annual installments beginning on March 12, 2027, so Cancelmi must remain eligible over time to receive the full amount. Following this grant, he holds 6,625 shares of Acadia Healthcare common stock.
Acadia Healthcare Company, Inc. director Daniel J. Cancelmi filed an initial ownership report on Form 3 for the company’s common stock. The filing shows a direct holding entry with total common shares beneficially owned following the reported date stated as 0.0000 shares.
Acadia Healthcare Company, Inc. announced board changes involving the retirement of one director and the appointment of another experienced healthcare finance executive. Wade D. Miquelon will retire from the Board at the 2026 annual meeting and will not stand for re-election, with the company stating his decision did not result from any disagreement regarding operations, policies or practices.
The Board expanded from 10 to 11 members and appointed Daniel Cancelmi as a Class III director and member of the Audit Committee, effective immediately, with his term running until the 2026 annual meeting. Following Mr. Miquelon’s retirement, the Board size will revert to 10 members as the number of Class III directors decreases from four to three. The company highlighted Mr. Cancelmi’s long-tenured leadership at Tenet Healthcare and broader healthcare finance experience, and noted there are no special appointment arrangements, family relationships or related-party transactions requiring disclosure.
Acadia Healthcare Company, Inc. — The Khrom reporting group amended its Schedule 13D disclosing aggregate beneficial ownership of 7,457,311 Shares of Common Stock as of March 10, 2026, representing approximately 8.09% of outstanding shares.
The filing states Khrom Investments directly holds 7,450,383 Shares, Khrom Capital has shared voting and dispositive power over those same 7,450,383 Shares, and Eric Khrom directly holds 6,928 Shares, for an aggregate total of 7,457,311 Shares. The outstanding share base cited is 92,211,777 Shares as of February 25, 2026 per the Issuer's Annual Report on Form 10-K.
Acadia Healthcare Company, Inc. executive Brian Farley reported a Form 4 showing a tax-related share disposition. On this date, he disposed of 1,915 shares of common stock at a price of $22.29 per share to cover tax withholding obligations, leaving him with 69,165 shares held directly.